Mylan

Pharmalot By Ed Silverman

Elizabeth Warren criticizes feds for a ‘shamefully weak’ deal with Mylan

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

The Pharmalot View By Ed Silverman

Health officials should reject latest gambit by EpiPen maker to feed at the public trough

Pharmalot By Ed Silverman

Mylan to pay $465 million to settle claims of shortchanging Medicaid

Pharmalot By Ed Silverman

Mylan overcharged Medicaid for EpiPen for years, despite warnings

First Opinion By Jennifer Brokaw

Cheap EpiPen alternative risks patients’ lives. I’ve seen it myself

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers

Pharmalot By Ed Silverman

Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid

Pharmalot By Ed Silverman

Lawmakers ask Justice Department to probe Mylan over Medicaid rebates

First Opinion By James R. Baker Jr.

EpiPen pricing controversy reflects larger issues in pharma industry

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Most Californians support proposed law to limit drug prices

The Pharmalot View By Ed Silverman

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

Business By Ike Swetlitz

Lawmakers lash out at Mylan over EpiPen profit revision

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan’s parent bloggers feel jilted thanks to price hikes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Congress probes FDA’s Office of Criminal Investigations

Business By Ike Swetlitz

Anger at EpiPen prices channeled at Mylan CEO in congressional hearing

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan CEO’s mom helped push EpiPen to schools